Pharmaceutical Preparations

PROMOTION AGREEMENT

                       This PROMOTION AGREEMENT is made as of December 1, 2001, by and between QUESTCOR PHARMACEUTICALS. INC. a California corporation (Questcor) and VSL PHARMACEUTICALS, INC., a Delaware corporation (VSL).

RECITALS

            A.      WHEREAS, VSL produces, markets and distributes a probiotic preparation of live freeze-dried lactic acid bacteria, developed specifically to provide the optimal concentration and types of healthy bacteria for the gastrointestinal tract and to be used in various gastrointestinal disorders under the trademark VSL#3 ; and

            B.      WHEREAS, Questcor is engaged in the business, among other things, of marketing pharmaceutical products; and

            C.      WHEREAS, VSL wishes to expand the promotion of VSL#3, and Questcor desires to have the right to promote and sell VSL#3, upon the terms specified herein.

AGREEMENT

            NOW, THEREFORE, in consideration of the mutual covenants herein set forth, and intending to be legally bound hereby, the parties hereto agree as follows:

1.     Definitions.

                        For purposes of this Agreement, the following terms shall have the corresponding meanings set forth below.

                        Affiliate means, with respect to any Person, any other Person which directly or indirectly controls, is controlled by, or is under common control with, such Person.  A Person shall be regarded as in control of another Person if it/he/she owns, or directly or indirectly controls, more than fifty percent (50%) of the voting securities (or comparable equity interests) or other ownership interests of the other Person, or if it/he/she directly or indirectly possesses the power to direct or cause the direction of the management of the other Person, whether through the ownership of voting securities, by contract or any other means whatsoever.

                        Agreement means this agreement, together with all appendices, exhibits and schedules hereto, and as the same may be amended or supplemented from time to time hereafter by a written agreement duly executed by authorized representatives of each party hereto.

                        Agreement Quarter means each three-month period commencing on the first day of January, April, July or October, as the ease may be during the Term. The first Agreement Quarter shall commence on the Effective Date and end on March 31,2002.

Co-Promotion Agreement

This Co-Promotion Agreement is entered as of May 7, 1999 (the "Effective Date") by and between Abbott Laboratories Inc. ("Abbott"), an Illinois corporation, with a place of business at 100 Abbott Park Road, Abbott Park, Illinois 60064-6400, and SangStat Medical Corporation ("SangStat") a Delaware corporation, with a place of business at 1505 Adams Drive, Menlo Park, California 94025.

Whereas, Abbott and SangStat are each developing a generic capsule formulation of cyclosporine which capsule is intended to be AB-rated equivalent to Neoral (as defined below);

Whereas, SangStat is currently marketing an oral solution cyclosporine product known as SangCya (Cyclosporine Oral Solution, USP [Modified]) that is AB-rated equivalent to Neoral;

Whereas, by combining SangStat's strengths in the transplant market, its portfolio of transplant-related products already on the market, and its technology in the field of at-home testing devices with Abbott's strengths in managed care and its technology in the field of assay development; Abbott and SangStat will create a stronger competitor to Novartis (as defined below), the market leader, than would otherwise prevail in the absence of this Agreement thereby enhancing competition;

Whereas, Abbott wishes SangStat to co-promote and sell Abbott's generic capsule formulation of cyclosporine under the terms and conditions set forth herein; and

Whereas, SangStat wishes Abbott to co-promote SangStat's generic capsule formulation of cyclosporine, along with SangCya and CycloTech (as defined below), under the terms and conditions set forth herein.

Now, therefore, in consideration of the foregoing, of the mutual covenants and undertakings contained herein, and of other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties intending to be legally bound hereby agree as follows:

1. Definitions
   
   
   
   1. "Abbott Detailing Commitment" has the meaning set forth in Section 3.2.3.
      
   2. "Acquiror" has the meaning set forth in Section 14.4.
      
   3. "Adverse Ruling" has the meaning set forth in Section 14.2.2.
      
   4. "Affiliate" means an entity controlling, controlled by, or under common control with a party to this Agreement. For purposes of this definition, "control" or any correlative form thereof, means the ownership of more than fifty percent of the voting stock of such entity, or if such entity is not a corporation, the ability to control the day-to-day operations and business of such entity.
      
   5. "ANDA" means an Abbreviated New Drug Application as such is defined by the FDA.
      
   6. "Base Rate" has the meaning set forth in Section 6.4.
      
   7. "Capsule Product" means a Party's, or any of its Affiliate's, generic capsule or tablet dosage form for which such Party either intends to seek, is seeking or has received Regulatory Approval and is an AB-rated product equivalent to Neoral or Sandimmune. The current expected Capsule Products are more particularly described in Exhibit A hereto.
      
   8. "Commercially Reasonable Efforts" means, with respect to each Party, efforts which are consistent with those utilized by such Party for its own internally-developed or in-licensed pharmaceutical products of similar market potential, at a similar stage of its product life, taking into account the existence of other competitive products in the market place or under development, the proprietary position of the product, the profitability of the product and other relevant factors.
      
   9. "Commission" means any commission due Abbott on SangCya, Sang-2000 or CycloTech.
      
   10. "Co-Promotion Committee" has the meaning set forth in Section 5.1.2.
       
   11. "Co-Promotion Plan" means, for any period, a written plan developed by SangStat and Abbott for such period that has been approved by the Executive Steering Committee and that sets forth the key elements of the sales and marketing strategy for the Products, including, without limitation, plans for promotional materials, clinical trials and studies, trade show participation, and advertising, which may include the elements set forth on Exhibit B.
       
   12. "CycloStat System" means the combination of the Abbott TDx assay and SangStat's CycloStat device.
       
   13. "CycloTech" means the dispensing device used in conjunction with SangCya, and which received 510(k) approval from the FDA on August 18, 1998, and which is more particularly described in Exhibit A.
       
   14. "CycloTech Commission Rate" has the meaning set forth in Section 6.5.3.
       
   15. "DDMAC" means the FDA's Division of Drug Marketing, Advertising and Communications.
       
   16. "Detailing" means the act of promoting a Product in the Territory through Physician Details and Sales Calls.
       
   17. "Detail Year" means, with respect to the Products, the calendar year. The first Detail Year shall commence on the earlier of Abbott's Launch Date for SangCya or ninety (90) days after the Effective Date and end December 31, 1999.
       
   18. "Development Committee" has the meaning set forth in Section 5.2.
       
   19. "Development Costs" means, with respect to a Product, the costs and expenses incurred by a Party in connection with designing and conducting (including, but not limited to, data monitoring, data collection, data analysis, physicians' and center fees, investigator meetings, external consultants and clinical research organizations) Phase IV clinical trials for such Product which have been approved by the Executive Steering Committee. Development Costs shall include the cost of all Product used in such clinical trials (calculated as the Manufacturing Cost for such Product), and reasonable internal costs directly relating to designing or conducting such clinical trials. The initial budget for Development Costs is set forth in Section 7.2.4. Development Costs do not include any overhead or other costs unless they are attributable to designing or conducting such clinical trials.
       
       
       146880

                                                                           Final

          CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE
      SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

                             CO-PROMOTION AGREEMENT

         This Co-promotion Agreement (hereafter, the "AGREEMENT") is entered
into as of October 29, 2003, by and between Kos Pharmaceuticals, Inc., a Florida
corporation ("KOS"), and Takeda Pharmaceuticals North America, Inc., a Delaware
corporation ("TPNA"), for the marketing  . . .

                              COPROMOTION AGREEMENT


                                     BETWEEN


                                  NOVAVAX, INC.


                                       AND


                           KING PHARMACEUTICALS, INC.





                                 JANUARY 8, 2001


   2


                                TABLE OF CONTENTS


                                                                                         
1.    DEFINITIONS.................................................................. . . .

PROMOTION AGREEMENT

                       This PROMOTION AGREEMENT is made as of December 1, 2001, by and between QUESTCOR PHARMACEUTICALS. INC. a California corporation (�Questcor�) and VSL PHARMACEUTICALS, INC., a Delaware corporation (�VSL�).

RECITALS

            A.      WHEREAS, VSL produces, markets and distributes a probiotic preparation of live freeze-dried lactic acid bacteria,  . . .

             CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH
                     THE SECURITIES AND EXCHANGE COMMISSION.
                        ASTERISKS DENOTE SUCH OMISSIONS.

                             CO-PROMOTION AGREEMENT

     This Co-promotion Agreement (hereafter, the "AGREEMENT") is entered into as
of April 12, 2005 (the "EFFECTIVE DATE"), by and between Kos Pharmaceuticals,
Inc., a Florida corporation and Kos Life Sciences, Inc., a Delaware corporation
(collectively, "KOS"), Duramed Pharmaceuticals, Inc., a Delaware corporation, . . .

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT WAS OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH RULE
24b-2, PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
OMITTED INFORMATION WAS REPLACED WITH ASTERISKS.

                             CO-PROMOTION AGREEMENT

THIS CO-PROMOTION AGREEMENT ("Agreement") is entered into as of July 14, 2004
("Effective Date") by and between Cardinal Health PTS, LLC, with an office at
7000 Cardinal Place, Dublin, Ohio 43017 and Bone Care International, Inc.,
having a  . . .

       THIS DOCUMENT MARKED [****] HAVE BEEN REDACTED AND HAVE BEEN FILED
           SEPARATELY WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION

================================================================================

                             CO-PROMOTION AGREEMENT

                                 BY AND BETWEEN

                         ASTRAZENECA PHARMACEUTICALS LP

                                       AND

                               ATHEROGENICS, INC.

                          DATED AS OF DECEMBER 22,  . . .

Portions of this exhibit marked [*] are requested to be treated confidentially.

CO-PROMOTION AGREEMENT

This CO-PROMOTION AGREEMENT (this �Agreement�), dated March 2, 2005, is entered into by and between SALIX PHARMACEUTICALS, INC., a California corporation (�Salix�) and ALTANA PHARMA US, INC., a Delaware corporation (�Altana�).

WHEREAS, Salix owns, develops, markets and manufactures rifaximin, an antibiotic marketed and sold under the name �Xifaxan^�� (the �Product�), the initial indication for which is the treatment of patients, twelve (12) years of age  . . .

Portions of this exhibit marked [*] are requested to be treated confidentially.

CO-PROMOTION AGREEMENT

This CO-PROMOTION AGREEMENT (this �Agreement�), dated March 2, 2005, is entered into by and between SALIX PHARMACEUTICALS, INC., a California corporation (�Salix�) and ALTANA PHARMA US, INC., a Delaware corporation (�Altana�).

WHEREAS, Salix owns, develops, markets and manufactures rifaximin, an antibiotic marketed and sold under the name �Xifaxan^�� (the �Product�), the initial indication for which is the treatment of patients, twelve (12) years of age  . . .

FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                             CO-PROMOTION AGREEMENT

         This CO-PROMOTION AGREEMENT (this "Agreement") is entered into and
effective as of this 4th day of October, 2004 (the "Effective Date"), by and
between SANTARUS, INC., a Delaware corporation ("Santarus"), and OTSUKA AMERICA
PHARMACEUTICAL, INC., a Delaware corporation ("Co-Promotion Partner").

         WHEREAS, Santarus has exclusive rights to market and distribute the
Products in the United States;

         WHEREAS,  . . .

                             CO-PROMOTION AGREEMENT

                                 BY AND BETWEEN

              SMITHKLINE BEECHAM CORPORATION D/B/A GLAXOSMITHKLINE

                                       AND

                                 ALLERGAN, INC.

                                       AND

                               ALLERGAN SALES LLC

                               SEPTEMBER 30, 2005

<PAGE>

                             CO-PROMOTION AGREEMENT

     This Co-Promotion Agreement (the "Co-Promotion Agreement" or this
" . . .